Bone Fractures Can Best Be Detected Using Artificial Intelligence

Bone Fractures: Artificial intelligence (AI) is an effective tool for fracture detection that has potential to aid clinicians in busy emergency departments, according to a study in Radiology, reports RSNA.

Missed or delayed diagnosis of fractures on X-ray is a common error with potentially serious implications for the patient. Lack of timely access to expert opinion as the growth in imaging volumes continues to outpace radiologist recruitment only makes the problem worse.

AI may help address this problem by acting as an aid to radiologists, helping to speed and improve fracture diagnosis.

To learn more about the technology’s potential in the fracture setting, a team of researchers in England reviewed 42 existing studies comparing the diagnostic performance in fracture detection between AI and clinicians. Of the 42 studies, 37 used X-ray to identify fractures, and five used CT.

The researchers found no statistically significant differences between clinician and AI performance. AI’s sensitivity for detecting fractures was 91-92%.

“We found that AI performed with a high degree of accuracy, comparable to clinician performance,” said study lead author Rachel Kuo, M.B. B.Chir., from the Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences in Oxford, England. “Importantly, we found this to be the case when AI was validated using independent external datasets, suggesting that the results may be generalizable to the wider population.”

The study results point to several promising educational and clinical applications for AI in fracture detection, Dr. Kuo said. It could reduce the rate of early misdiagnosis in challenging circumstances in the emergency setting, including cases where patients may sustain multiple fractures. It has potential as an educational tool for junior clinicians.

“It could also be helpful as a ‘second reader,’ providing clinicians with either reassurance that they have made the correct diagnosis or prompting them to take another look at the imaging before treating patients,” Dr. Kuo said.

Dr. Kuo cautioned that research into fracture detection by AI remains in a very early, pre-clinical stage. Only a minority of the studies that she and her colleagues looked at evaluated the performance of clinicians with AI assistance, and there was only one example where an AI was evaluated in a prospective study in a clinical environment.

“It remains important for clinicians to continue to exercise their own judgment,” Dr. Kuo said. “AI is not infallible and is subject to bias and error.”

SourceRSNA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”